Table 1 Participant demographic and clinical characteristics

From: Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis

 

Variable

Total sample (N = 30)

Demographic

Age, years; mean (SD)

23.2 (4.7)

 

Age range, years

18–35

 

Sex, male/female

30/0

 

Ethnicity (White/Black/Asian/Mixed)

16/6/4/4

 

Handedness, right/left

26/4

 

Education, years; mean (SD)

13.2 (1.9)

Clinical

CHR-P Subtypea (BLIPS/APS/GRD)

6/23/1

 

CAARMS attenuated positive symptomsb; mean (SD)

11.7 (3.3)

 

Transition to psychosis (yes/no)c

4/26

 

Baseline anxiety scored; mean (SD)

35.6 (8.7)

 

GF social score; mean (SD)

6.8 (1.5)

 

GF role score; mean (SD)

7.0 (1.7)

 

Current antidepressant medication (yes/no)

8/22

 

Current antipsychotic medication (yes/no)

0/30

 

Current benzodiazepine medication (yes/no)

1/29

Substance Use

Current smoker (yes/no)

17/13

 

Cigarettes/day; mean (SD)

9.8 (6.0)

 

Cannabis usee; median (range)

2 (0–4)

 

Alcohol, AUDIT total; mean (SD)

7.2 (7.7)

  1. aComprehensive Assessment of At-Risk Mental States (CAARMS) subgroup; BLIPS brief limited intermittent psychotic symptoms, APS attenuated psychotic symptoms, GRD genetic risk and deterioration
  2. bSum of the global (severity) ratings for positive subscale items (P1-P4) of the CAARMS
  3. cThe 4 transitions occurred within 26 months but the follow up is still ongoing
  4. dMean of pre-scan anxiety scores across conditions as measured by the State Trait Anxiety Inventory (STAI)
  5. eCannabis use: 0 = never, 1 = experimental use (tried occasionally), 2 = occasional use (small quantities from time to time), 3 = moderate use (moderate quantities regularly / large amounts occasionally), 4 = severe use (frequently used large quantities, often to intoxication/debilitation). AUDIT alcohol use disorders identification test, CHR-P clinical high risk for psychosis, GF global functioning (role and social) scale
Back to article page